Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -982.60K | -1.29M | -1.17M | -1.31M | -1.81M |
| Total Depreciation and Amortization | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 311.90K | 307.50K | 296.70K | 312.10K | 296.80K |
| Change in Net Operating Assets | 311.90K | 624.90K | -1.60K | 158.80K | 994.00K |
| Cash from Operations | -358.20K | -357.60K | -869.60K | -839.90K | -523.10K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.36M | 335.00K | 985.00K | 530.00K | 540.00K |
| Total Debt Repaid | -68.80K | -80.10K | -86.80K | -34.10K | -70.20K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 75.00K | 150.00K | 0.00 | 0.00 |
| Cash from Financing | 1.29M | 329.90K | 1.05M | 495.90K | 469.80K |
| Foreign Exchange rate Adjustments | 100.00 | 300.00 | 100.00 | 0.00 | 400.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 933.00K | -27.40K | 178.80K | -344.00K | -53.00K |